| HOME >> BIOLOGY >> TECHNOLOGY |
PHILADELPHIA and LYON, France, Jan. 13 /PRNewswire-USNewswire/ -- ERYtech Pharma, French Biotechnology Company, and the Penn Jersey Region of American Red Cross are pleased to announce the signature of an agreement concerning the GMP clinical batches production of ERYtech Pharma's products in the United States.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090113/DC58023LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO)
ERYtech Pharma's co-founder and COO, Pierre-Olivier Goineau says, "this agreement allows ERYtech Pharma to be industrially present in the United States; it is an important step for the development of our products."
"This partnership enables the American Red Cross to show patients and donors that we are committed to providing the best services available," says Brigid O'Neill-LaGier, Chief Executive Officer of the American Red Cross Penn-Jersey Blood Services Region.
ERYtech Pharma's Co-Founder and CEO, Yann Godfrin concludes, "We are pleased to have reached this agreement and we think already to other projects of partnership with the American Red Cross for the development of our products."
About ERYtech Pharma
ERYtech Pharma is a leading biotechnology company developing next generation medicinal products making a huge positive impact on the lives of patients with serious unmet clinical needs.
A pioneer in the encapsulation of therapeutic molecules inside red blood cells, it is developing a pipeline of innovative therapeutics in orphan indications or underserved subpopulation of high risk patient's through its proprietary technology of entrapment and in-depth exploration of red cell physiologic properties.
ERYtech is foc
'/>"/>
| SOURCE American Red Cross, Penn-Jersey Region; ERYtech Pharma Copyright©2009 PR Newswire. All rights reserved |